Ayako Suzuki

Elevated Homocysteine is Associated With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease in a Sex- and Menopause-Specific Manner.

Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD.

Human BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas construction and usage.

Epidemiology and Risk Determinants of Drug-Induced Liver Injury: Current Knowledge and Future Research Needs.

Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.

Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records

Sex differences in alcohol-related liver disease, viral hepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatocellular carcinoma

The connection between Bayesian networks and adverse outcome pathway (AOP) networks and how to use it for predicting drug toxicity.

Differential effects of synthetic estrogen on serum homocysteine levels before and after menopause.

Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIV.

Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women.

Lower hepatic <i>CBS</i> and <i>PEMT</i> expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model

Longer Breastfeeding Duration Is Associated With Decreased Risk of Hepatic Fibrosis Among Young Women With Nonalcoholic Fatty Liver Disease.

Metabolic dysfunction-associated steatotic liver disease: Emerging risk factors for adverse pregnancy outcomes.

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study

AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.

Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression

Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.

Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.

Nutrition assessment and MASH severity in children using the Healthy Eating Index.

Vitamin B₁₂ and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.

<i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program

Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression.

Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis.

APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

A <i>MUC5B</i> Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality

A &lt;i&gt;MUC5B&lt;/i&gt; Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality.